EBFI Activity Controls Leukemia Sensitivity to Inotuzumab Ozogamicin

被引：0

作者：

Escherich, Carolin S. ^{[1
]}

Li, Zhenhua ^{[2
]}

Barnett, Kelly R. ^{[1
]}

Li, Yizhen ^{[1
]}

Walker, Megan ^{[1
]}

Yang, Wenjian ^{[2
]}

Huang, Xin ^{[1
]}

Yu, Jiyang ^{[1
]}

Stock, Wendy ^{[3
]}

Paietta, Elisabeth ^{[4
]}

Konopleva, Marina ^{[5
]}

Kornblau, Steven M. ^{[6
]}

Litzow, Mark R. ^{[7
]}

Inaba, Hiroto ^{[1
]}

Pui, Ching-Hon ^{[1
]}

Loh, Mignon L. ^{[8
]}

Savic, Daniel ^{[1
]}

Yang, Jun J. ^{[1
]}

机构：

[1] St Jude Childrens Res Hosp, Memphis, TN USA

[2] St Jude Childrens Res Hosp, Dept Pharm & Pharmaceut Sci, Memphis, TN USA

[3] Univ Chicago, Chicago, IL USA

[4] Montefiore Med Ctr, Dept Oncol, Bronx, NY USA

[5] Albert Einstein Coll Med, Bronx, NY USA

[6] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX USA

[7] Mayo Clin, Div Hematol, Rochester, MN USA

[8] Univ Washington, Seattle Childrens Hosp, Ben Towne Ctr Childhood Canc Res, Fred Hutch Canc Ctr, Seattle, WA USA

来源：

BLOOD | 2024年 / 144卷

关键词：

D O I：

10.1182/blood-2024-198800

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：830 / 831

页数：2

共 50 条

[41] Inotuzumab ozogamicin in the management of acute lymphoblastic leukaemia
Morley, N. J.
Marks, D. I.
EXPERT REVIEW OF ANTICANCER THERAPY, 2016, 16 (02) : 159 - 164
[42] Phase 2 study of inotuzumab ozogamicin for measurable residual disease in acute lymphoblastic leukemia in remission
Jabbour, Elias
Haddad, Fadi G.
Short, Nicholas J.
Senapati, Jayastu
Jain, Nitin
Sasaki, Koji
Jorgensen, Jeffrey
Wang, Sa A.
Alvarado, Yesid
Wang, Xuemei
Dinardo, Courtney
Masarova, Lucia
Kadia, Tapan
Garris, Rebecca S.
Ravandi, Farhad
Kantarjian, Hagop
BLOOD, 2024, 143 (05) : 417 - 421
[43] Indirect Treatment Comparison of Inotuzumab Ozogamicin Versus Blinatumomab for Relapsed or Refractory Acute Lymphoblastic Leukemia
Irina Proskorovsky
Yun Su
Kyle Fahrbach
Erik Vandendries
Véronique Pagé
Uchenna Onyekwere
Yunyang Wang
Joseph C. Cappelleri
Matthias Stelljes
Advances in Therapy, 2019, 36 : 2147 - 2160
[44] Inotuzumab Ozogamicin (Besponsa®) for Patients with relapsed or refractory acute lymphoblastic Leukemia (r/r ALL)
不详
ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 (1-2) : 66 - 66
[45] Inotuzumab ozogamicin versus standard of care in Asian patients with relapsed/refractory acute lymphoblastic leukemia
Naohito Fujishima
Toshiki Uchida
Yasushi Onishi
Chul Won Jung
Yeow Tee Goh
Kiyoshi Ando
Ming Chung Wang
Chiho Ono
Miyako Matsumizu
M. Luisa Paccagnella
Barbara Sleight
Erik Vandendries
Yosuke Fujii
Masayuki Hino
International Journal of Hematology, 2019, 110 : 709 - 722
[46] Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia (R/R ALL).
Bhojwani, Deepa
Sposto, Richard
Shah, Nirali
Rodriguez, Vilmarie
O'Brien, Maureen Megan
McNeer, Jennifer Lynn
Loh, Mignon L.
Rheingold, Susan R.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[47] Feasibility of Allografting in Patients with Advanced Acute Lymphoblastic Leukemia After Salvage Therapy With Inotuzumab Ozogamicin
Kebriaei, Partow
Wilhelm, Kaci
Ravandi, Farhad
Brandt, Mark
de Lima, Marcos
Ciurea, Stefan
Worth, Laura
O'Brien, Susan
Thomas, Deborah
Champlin, Richard E.
Kantarjian, Hagop
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2013, 13 (03): : 296 - 301
[48] Indirect Treatment Comparison of Inotuzumab Ozogamicin Versus Blinatumomab for Relapsed or Refractory Acute Lymphoblastic Leukemia
Proskorovsky, Irina
Su, Yun
Fahrbach, Kyle
Vandendries, Erik
Page, Veronique
Onyekwere, Uchenna
Wang, Yunyang
Cappelleri, Joseph C.
Stelljes, Matthias
ADVANCES IN THERAPY, 2019, 36 (08) : 2147 - 2160
[49] Antibody-Drug Conjugates of Calicheamicin Derivative: Gemtuzumab Ozogamicin and Inotuzumab Ozogamicin
Ricart, Alejandro D.
CLINICAL CANCER RESEARCH, 2011, 17 (20) : 6417 - 6427
[50] Inotuzumab ozogamicin versus standard of care in Asian patients with relapsed/refractory acute lymphoblastic leukemia
Fujishima, Naohito
Uchida, Toshiki
Onishi, Yasushi
Jung, Chul Won
Goh, Yeow Tee
Ando, Kiyoshi
Wang, Ming Chung
Ono, Chiho
Matsumizu, Miyako
Paccagnella, M. Luisa
Sleight, Barbara
Vandendries, Erik
Fujii, Yosuke
Hino, Masayuki
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2019, 110 (06) : 709 - 722

← 1 2 3 4 5 →